Aegis Therapeutics to Present at the "4th Modern Drug Discovery & Development Summit" in San Diego, CA, October 15-17, 2008
September 08, 2008 04:00 ET | Source: Aegis Therapeutics LLC Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwire - September 8, 2008) - Aegis Therapeutics, a drug delivery technology licensing company and leader in transmucosal drug delivery, will present a talk entitled: "Non-Invasive Peptide Delivery, Reformulation, and the Pharma Finance Environment" at the GTCbio "4th Modern Drug Discovery & Development Summit." The conference will be held on October 15-17, 2008, at the Hilton La Jolla Torrey Pines, San Diego, CA. Dr. Edward T. Maggio, President and CEO of Aegis, will address key issues in peptide reformulation such as achieving adequate non-invasive bioavailability, preventing peptide aggregation, and minimizing immunogenicity, as well as opportunities and benefits of reformulation of peptide drugs amenable to 505(b)2 FDA regulatory treatment such as minimized business, regulatory, and clinical risks; expanded clinical indications; greater patient acceptance; increased product sales, and maximizing value extraction from an existing product franchise.
Information about the conference may be obtained from the following website: http://www.gtcbio.com/M3D_2008.htm.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website at: http://www.aegisthera.com.
Contact Information: Contact: Ralph Barry Chief Business Officer Aegis Therapeutics LLC 1-858-618-1400 Ext. 102 Email:
http://aegisthera.com